Skip to content
Lisata Therapeutics
Lisata Therapeutics
Lisata Therapeutics
Lisata Therapeutics
Main Menu
Careers
Contact Us
Policies
Search for:
Search
BOLSTER Trial
FORTIFIDE Trial
About Us
Show submenu
Overview
Management Team
Board of Directors
Pipeline
Show submenu
Overview
Advanced Solid Tumors
Certepetide (LSTA1)
Research & Technology
Show submenu
Overview
CendR Platform®
– Targeted penetration technology to enhance drug delivery to advanced solid tumors
CD34+ Cell Technology
Show submenu
Coronary Microvascular Dysfunction (CMD)
XOWNA®
Critical Limb Ischemia (CLI)
LSTA12 (HONEDRA® in Japan)
Diabetic Kidney Disease (DKD)
LSTA201
No-Option Refractory Disabling Angina (NORDA)
LSTA14 (OLOGO™ in the USA)
CD34+ Cell Technology Publications
Publications
Investors & News
Show submenu
Overview
News & Events
Show submenu
Press Releases
Events & Presentations
Media Coverage
Financials & Filings
Show submenu
Quarterly Results
SEC Filings
Stock Information
Show submenu
Stock Quote & Chart
Historical Price Lookup
Analyst Coverage
Corporate Governance
Show submenu
Docs & Charters
Management Team
Board of Directors
Historical Information
Show submenu
Historical Press Releases
Historical SEC Filings
Investor Resources
Show submenu
Stockholder Information
Investor FAQs
Email Alerts
IR Contact
Policies & Disclosures
Patients & Families
Show submenu
Overview
Cholangiocarcinoma (Bile Duct Cancer) Signs, Symptoms and Treatment
Metastatic Pancreatic Ductal Adenocarcinoma Symptoms, Signs & Treatment
Clinical Trials
Home
/
Uncategorized
Category:
Uncategorized